Results 181 to 190 of about 529,954 (381)
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Cardiovascular Health in Women—Across the Lifespan
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar +5 more
wiley +1 more source
Incessant focal atrial tachycardia: A surgically remediable cause of cardiomyopathy
Lee V. Giorgi +2 more
openalex +1 more source
Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang +4 more
wiley +1 more source
Temporary Atrial Electrode for the Treatment of Supraventricular Tachycardia After Cardiac Operations [PDF]
Hormoz Mehmanesh +2 more
openalex +1 more source
Primary heart involvement (pHI) is a severe but often overlooked complication of systemic sclerosis (SSc), linked to heart failure, arrhythmias and mortality. In a study of 600 patients from the Italian SPRING‐SIR registry, 25% had ECG or echocardiographic signs of pHI at baseline, associated with older age, diffuse skin disease and intestinal symptoms.
Antonio Tonutti +91 more
wiley +1 more source

